



# Cardiac implantable electronic device infection prevention ?

Sok-Sithikun BUN, MD, PhD  
French Riviera University Hospital, Nice, FRANCE

## Disclosure

Speaker name:

**Sok-Sithikun BUN**

I have the following potential conflicts of interest to report:

~~Consulting~~

~~Employment in industry~~

~~Shareholder in a healthcare company~~

~~Owner of a healthcare company~~

~~Other(s)~~

**I do not have any potential conflict of interest**

# CIED infection: Incidence



## CIED-related infections, <12 months<sup>354,639,641,645,685,695,702</sup>

Superficial infection<sup>354</sup>

Pocket infections<sup>354</sup>

Systemic infections<sup>354</sup>

## CIED-related infections, >12 months<sup>702–709</sup>

Pocket infections<sup>702</sup>

Systemic infections<sup>702,705</sup>

0.7 – 1.7

1.2


0.4

0.5

1.1 – 4.6

1.3

0.5 – 1.2



# CIED Infection: a major concern



- Stable or ↗ incidence
  - 1.45 to 3.41 % from 2000 to 2012 (USA National survey)
- Significant morbidity and mortality : in-hospital or 30-day mortality of 5-8 %
  - Long-term mortality = 1.5-2.4 x in comparison with non-infected patients
  - 6-15 % at 1 year / 14-33 % at 3 years.
- Financial healthcare burden
  - 20623-23234 euros in France
  - 36931 euros in the UK
  - 15516 to 337886 euros in the USA

*Joy PS et al. Heart Rhythm 2017*

*Maytin M et al. Circ AE 2012*

*Sohail MR et al. PACE 2015*

*Clementy N et al. Europace 2018*

# Risk factors

Factors	Prospective + retrospective studies				Prospective studies only			
	Studies (n)	Total (n)	Pooled estimate	P-value	Studies (n)	Total (n)	Pooled estimate	P-value
Patient-related factors								
ESRD <sup>a</sup>	8	3045	8.73 (3.42–22.31)	0.00001	NA			
History of device infection	4	463	7.84 (1.94–31.60)	0.004	NA			
Fever prior to implantation	3	6652	4.27 (1.13–16.12)	0.03	2	6580	5.34 (1.002–28.43)	0.05
Corticosteroid use	10	3432	3.44 (1.62–7.32)	0.001	3	1349	2.10 (0.47–9.32)	0.33
Renal insufficiency <sup>b</sup>	5	2033	3.02 (1.38–6.64)	0.006	NA			
COPD	6	2810	2.95 (1.78–4.90)	0.00003	2	2393	2.30 (0.97–5.48)	0.06
NYHA class $\geq 2$	3	2447	2.47 (1.24–4.91)	0.01	2	2393	2.77 (1.26–6.05)	0.01
Skin disorders	4	6810	2.46 (1.04–5.80)	0.04	2	6519	2.60 (0.88–7.70)	0.08
Malignancy	6	1555	2.23 (1.26–3.95)	0.006	NA			
Diabetes mellitus	18	11 839	2.08 (1.62–2.67)	<0.000001	7	9815	1.88 (1.19–2.98)	0.007
Heparin bridging	2	6373	1.87 (1.03–3.41)	0.04	NA			
CHF	6	1277	1.65 (1.14–2.39)	0.008	NA			
Oral anticoagulants	9	8527	1.59 (1.01–2.48)	0.04	3	7271	1.18 (0.44–3.11)	0.75
Procedure-related factors								
Procedure duration	9	4850	9.89 (0.52–19.25)	0.04	6	4508	13.04 (–0.64 to 26.73)	0.06
Haematoma	12	14 228	8.46 (4.01–17.86)	<0.000001	6	9715	9.33 (2.84–30.69)	0.0002
Lead repositioning	5	1755	6.37 (2.93–13.82)	0.000003	4	1659	7.03 (2.49–19.85)	0.0002
Inexperienced operator <sup>c</sup>	2	1715	2.85 (1.23–6.58)	0.01	2	1715	2.85 (1.23–6.58)	0.01
Temporary pacing	10	10 683	2.31 (1.36–3.92)	0.002	4	8683	3.29 (1.87–5.80)	0.00004
Device replacement/revision/upgrade	26	21 214	1.98 (1.46–2.70)	0.00001	8	8793	0.95 (0.49–1.87)	0.89
Generator change	20	12 134	1.74 (1.22–2.49)	0.002	6	2139	0.91 (0.37–2.22)	0.83
Antibiotic prophylaxis	16	14 166	0.32 (0.18–0.55) <sup>d</sup>	0.00005	11	10 864	0.29 (0.13–0.63)	0.002
Device-related factors								
Epicardial leads	3	623	8.09 (3.46–18.92)	0.000001	NA			
Abdominal pocket	7	4017	4.01 (2.48–6.49)	<0.000001	2	2268	5.03 (1.96–12.91)	0.0008
$\geq 2$ leads	6	1146	2.02 (1.11–3.69)	0.02	NA			
Dual-chamber device	14	45 224	1.45 (1.02–2.05)	0.04	7	12 102	1.28 (0.73–2.25)	0.38

**Blomström-Lundqvist C et al. International consensus document on how to prevent, diagnose, and treat CIED infections. Eur Heart J 2020**

- **Procedure-related:**

- Haematoma: Risk x 9
- Early reintervention
- Device replacement / Upgrade procedures
- CRT/ICD compared with simple pacemaker implantation
- Procedure duration
- Operator experience: risk ↗ when allocating generator changes to inexperienced operators

- **Patient-related:**

- End-stage renal disease
- Diabetes
- COPD
- Younger age
- Prior device infection
- Malnutrition


*Olsen T et al. Danish device-cohort study. Eur Heart J 2019*

*Blomström-Lundqvist C et al. International consensus document on how to prevent, diagnose, and treat CIED infections. Eur Heart J 2020*



# General considerations (1)

- Delay implantation if clinical signs of active infection and/or fever until afebrile > 24 h
- Avoid temporary transvenous pacing / prefer jugular or axillary vein access



*Bun SS et al. Ann Cardiol Angeiol 2020*

- Temporary pacing positively correlated to infection (OR 2.46) / fever within 24 h (OR 5.83) in a survey of 6319 patients

*Traykov V et al. Europace 2019*

# General considerations (2)


Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	
Administration of pre-operative antibiotic prophylaxis within 1 h of skin incision is recommended to reduce risk of CIED infection. <sup>641,643,686</sup>	I	A	<ul style="list-style-type: none"> <li>1-2 g i.v. Cefazolin/Flucoxacillin 30-60 min before</li> <li>15 mg/kg Vancomycin 90-120 min before</li> <li>Post-operative antibiotics do not infection ↘</li> </ul>
Chlorhexidine – alcohol instead of povidone-iodine – alcohol should be considered for skin antisepsis. <sup>647,648</sup>	IIa	B	
In patients undergoing a reintervention CIED procedure, the use of an antibiotic-eluting envelope may be considered. <sup>685,688</sup>	IIb	B	




# Chlorhexidine preferred

- RCT including 2456 patients:























Chlorhexidine-alcohol \ short-term intravascular catheter related-infections (vs povidone-iodine-alcohol)



VS



# Measures to decrease infections

Pre-procedural	Peri-procedural	Post-procedural
Confirm indication 	Alcoholic chlorhexidine  Adhesive iodophor-impregnated drapes 	Post-operative antibiotic 
Delay implantation if infection 	Glove change/ Remove outer glove of a double-glove before incision 	Adequate dressing for 2-10 d 
Avoid haematoma: Discontinue antiplatelets (1 w) / VKA in higher-risk patients  LMWH/Bridging 	Antibiotic envelope in high-risk patients 	Patient instructions on wound care 
Hair removal with electric clippers 	Local instillation of antiseptics/antibiotics in the pocket 	Reconsider indication for reintervention 
Avoid temporary transvenous pacing and/or central venous lines 	Braided sutures 	Haematoma evacuation 
Antibiotic prophylaxis 	Non-powdered gloves recommended  Capsulectomy may not be performed 	
Continuous surveillance programme of infection rates 	Vigorous pocket irrigation 	

# Measures to decrease infections

## Pre-procedural

Confirm indication



Safe without hair stud  
For adults and children, one m...  
needs all require



instillation of anti  
pocket

d sutures

powdered gloves r  
capsulectomy ma

ous pocket irriga

## Post-procedural

Post-operative antibiotic

Adequate dressing for 2-10 d



Patient instructions on wound care



## Suture types

Absorbable

Non-absorbable

Braided

Monofilament

Braided

Monofilament

Vicryl

Vicryl rapide

Monocryl

Fast absorbing gut

Chromic gut

Ethibond


Silk

Ethilon



# Per-procedural measures

## Double your gloves



Rinsing the device pocket with normal saline solution before wound closure should be considered.<sup>683,684</sup>

**Ila**

**C**


*Glikson M et al. ESC Guidelines Cardiac Pacing 2021*

## Vigorous irrigation with saline



# Antibiotic envelope

- 6983 patients randomized : pocket revision / generator replacement / upgrade or initial CRT-D implantation (WRAP-IT study)
- Minocycline/Rifampicin
- Infections (system extraction):  
25 in TYRX® (0.7 %) vs 42 (1.2 %) in control (HR 0.6)
- FU  $20.7 \pm 8.5$  mo
- Lower-than-expected rate of infections (immunosuppressive treatments, dialysis excluded)





# Risk factors

## • Procedure-related:

- Haematoma: Risk x 9
- Early reintervention
- Device replacement / Upgrade
- CRT/ICD
- Procedure duration
- Operator experience

## • Modifiable

- No bridging / Careful haemostasis
- Reassess necessity
- Reassess necessity
- CSP ?
- Experienced operator
- Experienced operator

## ACTIONS

## • Patient-related:


- End-stage renal disease
- Diabetes
- COPD
- Younger age
- Prior device infection
- Malnutrition

## • Modifiable

- NA
- Better glycaemic control
- NA
- Leadless pacemaker / Epicardial ?
- Leadless pacemaker / Epicardial ?
- Optimal nutrition


# Secondary prevention

- Reimplantation delayed until blood cultures are negative for at least > 72 h after extraction
- Reassess indication +++
  - 1/3 are not reimplanted after extraction
- Temporary pacemaker (ipsilateral active fixation strategy) in pacemaker-dependent patients requiring appropriate antibiotic treatment before reimplantation
- Leadless pacemakers / Entirely subcutaneous ICD
  - Wearable defibrillator (Life Vest, Zoll) as a bridge to reimplantation
- Antibiotic prophylaxis not recommended for CIED patients undergoing dental, respiratory, GI, genitourinary or cardiac procedures



# Consider alternatives in high-risk patients...

**Leadless pacemaker**




## **Reimbursement:**

- Prior device infection
- Complex/complicated venous access (dialysis)

(Leadless pacemakers infection = 0.27 %)

*Darlington D et al. Indian Pacing Electrophysiol J 2022*


**Entirely subcutaneous ICD**



(S-ICD infection = 2.4 % over 3 years)

*Boersma L et al. The EFFORTLESS study. JACC 2017*

# Secondary prevention



*Blomström-Lundqvist C et al. International consensus document on how to prevent, diagnose, and treat CIED infections. Eur Heart J 2020*




# TEP scan before reimplantation RHYTHM



TEP Scan may help excluding  
« concealed »  
inflammatory/infectious  
process allowing safe  
reimplantation after lead  
extraction for endocarditis

## Results



PET/CT performed 2 months after lead extraction for endocarditis complicating a DDD pacemaker in a 53-yo female revealed an uptake on the right coxofemoral joint, despite normal CRP. **Patient 1** received additional intravenous antibiotics and a second PET/CT still showed uptake, then delaying reimplantation.



**Patient 2**, a 79-yo male with ischaemic cardiomyopathy and a significant uptake on the PET/CT 7 weeks after extraction, at the region of explantation, could be reimplanted endocardially with a CRT-D, after normalization of the uptake on a second PET/CT.




**Patient 3**, a 74-yo female with dilated cardiomyopathy could be reimplanted with a CRT-D after eradication of dental abscesses and removal of a benign ovarian tumor detected on the PET/CT realized 8 weeks after lead extraction (endocarditis). No complication occurred during the follow-up at one year.



***Bun SS et al. Usefulness of Positron Emission Tomography to guide reimplantation after lead extraction for endocarditis. JESFC 2016.***



- CIED Infections = Major concern
- Actions to modify risk factors
- « Prévenir plutôt que guérir »



# Thank you !

